NCT07150416View on ClinicalTrials.gov

Nebulized Inhalation of Recombinant Human p53 Adenovirus Injection for Treatment of Multiple Ground-Glass Lung Nodules: A Single-Arm Clinical Study

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

December 1, 2026

Study Completion Date

February 1, 2027

Conditions
Multiple Pulmonary Ground-Glass NodulesLung NeoplasmsPrecancerous Conditions
Interventions
DRUG

Recombinant Human Ad-p53 Injection

A replication-deficient recombinant human type 5 adenovirus vector encoding the human wild-type p53 tumor suppressor gene. For this study, it will be administered via nebulized inhalation.

Trial Locations (1)

510120

The First Affiliated Hospital of Guangzhou Medical University, Guangzhou

All Listed Sponsors
collaborator

Shenzhen SiBiono GeneTech Co.,Ltd

INDUSTRY

lead

The First Affiliated Hospital of Guangzhou Medical University

OTHER